文献速递肿瘤 PET/CT

[68Ga]Ga-PSMA-11 PET/CT预测临床显著前列腺癌:筛选主动监测患者的潜在工具

Prediction of clinically significant prostate cancer by [68 Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-12-19

本研究回顾性分析147例活检初诊为ISUP GG 1和2级前列腺癌、术前接受[68Ga]Ga-PSMA-11 PET/CT的患者,以根治性前列腺切除术后病理为金标准。114例采用PRIMARY评分,评分3–5分者83%为临床显著前列腺癌(csPCa),评分5分者全部为csPCa;PRIMARY评分敏感度77%、特异度58%、阳性预测值83%,与ISUP GG中度相关(Rho=0.54,p<0.001),识别csPCa的可靠性显著优于PIRADS评分。

要点

  • PRIMARY评分3–5分的77例中64例(83%)为csPCa,评分5分者全部为csPCa。
  • PRIMARY评分敏感度77%、特异度58%、阳性预测值83%,与ISUP GG中度相关(Rho=0.54,p<0.001)。
  • PIRADS评分敏感度86%、特异度25%、阳性预测值68%,与ISUP GG无显著相关(p=0.281)。

核心结论

  • [68Ga]Ga-PSMA-11 PET/CT有望区分高风险前列腺癌患者与适合主动监测的患者,可能有助于识别csPCa。

研究设计与样本

  • 回顾性研究,纳入147例活检初诊为ISUP GG 1和2级前列腺癌、术前接受[68Ga]Ga-PSMA-11 PET/CT的患者,以根治性前列腺切除术后病理为最终病理报告。
  • 其中114例采用PRIMARY评分,并记录可获得的mpMRI-PIRADS评分,与病理结果进行相关性分析。

主要发现

  • 114例采用PRIMARY评分者中,37例评分为1和2分者里19例(51%)诊断为csPCa。
  • 77例PRIMARY评分3–5分者中64例(83%)为csPCa,每位PRIMARY评分5分者均为csPCa。
  • PRIMARY评分与ISUP GG呈中度相关(Rho=0.54,p<0.001),统计显示两者显著相关(p<0.001)。
  • PIRADS评分与ISUP GG无实质性相关,统计显示两者无显著相关(p=0.281)。
  • PRIMARY评分识别csPCa的可靠性显著优于PIRADS评分。

关键数值与推荐

  • PRIMARY评分:敏感度77%、特异度58%、阳性预测值83%。
  • PIRADS评分:敏感度86%、特异度25%、阳性预测值68%。
  • csPCa定义为ISUP GG 2级及以上。

临床怎么用

  • 原文结论认为[68Ga]Ga-PSMA-11 PET/CT有望用于区分高风险前列腺癌患者与适合主动监测的患者,可能有助于识别csPCa。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In our study, our aim was to investigate the role of [68 Ga]Ga-PSMA-11 PET /CT imaging in the diagnosis of clinically significant prostate cancer (csPCa) (ISUP GG 2 and higher) in patients initially diagnosed with ISUP GG 1 and 2 after prostate biopsy. MATERIALS AND METHODS: We retrospectively reviewed 147 patient records in whom [68 Ga]Ga-PSMA-11 PET/CT imaging was performed preoperatively. All patients were initially diagnosed with ISUP GG 1 and 2 PCa by biopsy. Final pathology reports were obtained after radical prostatectomy. The [68 Ga]Ga-PSMA-11 PET/CT images were evaluated to determine the PRIMARY score. Patients' mpMRI-PIRADS scores were also recorded when available and analyzed in correlation with the pathology results. RESULTS: For the 114 patients scored using PRIMARY, 19 out of 37 patients with scores of 1 and 2 (51%) were diagnosed with csPCa. Of the 77 patients with PRIMARY scores between 3 and 5, 64 (83%) had csPCa. Notably, every patient with a PRIMARY score of 5 had csPCa. PRIMARY scoring had a sensitivity of 77% and specificity of 58%, with a positive predictive value of 83%. A moderate correlation was observed between PRIMARY scores and ISUP GG (Rho = 0.54, p < 0.001). In contrast, the PIRADS score displayed a sensitivity and specificity of 86% and 25% respectively, with a positive predictive value of 68%. No substantial correlation was found between PIRADS and ISUP GG. Statistical analysis revealed a significant correlation between PRIMARY and ISUP GG (p < 0.001), but not between PIRADS and ISUP GG (p = 0.281). Comparatively, PRIMARY scoring was significantly more reliable than PIRADS scoring in identifying csPCa. CONCLUSION: [68 Ga]Ga-PSMA-11 PET/CT imaging is promising for distinguishing high-risk prostate cancer patients from those apt for active surveillance, potentially aiding in the identification of csPCa.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Akcay K, Kibar A, Sahin OE, et al. Prediction of clinically significant prostate cancer by [68 Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance. Eur J Nucl Med Mol Imaging. 2023. PMID: 38112777. doi:10.1007/s00259-023-06556-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。